KRAS and exocrine pancreatic carcinoma: Although all four PDAC cell lines used in this study have K-ras mutation at codon 12[49], the efficacy of IGF1R inhibitors against pancreatic carcinoma is independent of K-ras mutation status, and thus IGF1R inhibitors might be clinically useful in PDAC patients irrespective of K-ras status in PDAC patients.